<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784784</url>
  </required_header>
  <id_info>
    <org_study_id>08-0189-A</org_study_id>
    <secondary_id>CRT113936</secondary_id>
    <nct_id>NCT00784784</nct_id>
  </id_info>
  <brief_title>Zanamivir Versus Trivalent Split Virus Influenza Vaccine</brief_title>
  <acronym>Stop-Flu-2</acronym>
  <official_title>A Pilot Study for a Randomized Controlled Trial to Compare Trivalent Split Virus Influenza Vaccine to Seasonal Antiviral Prophylaxis in Healthcare and Other Healthy Adults: Assessment of Zanamivir Versus Vaccine (Stop-Flu-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai Hospital, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This unblinded pilot study is intended to assess the feasibility of a larger double-blind,
      randomized control trial. For the larger trial the investigators are interested in
      understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors
      for influenza infection in healthy adults, and in assessing the safety and tolerability of
      seasonal antiviral prophylaxis in healthcare workers.

      The pilot study will be assessing the rate of infection with influenza and the rate of
      adherence to long-term zanamivir in 60 healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have demonstrated that zanamivir and oseltamivir are effective in preventing
      influenza infection and illness when used either as prophylaxis after exposure to a household
      contact with influenza or when taken for several weeks at the height of influenza activity in
      the general community. However, the longest duration of prophylaxis with neuraminidase
      inhibitors in two clinical trials, to date, has been six weeks.

      Antiviral medication will likely have an important role in the response to the next influenza
      pandemic. Additionally, there may be indications for use during seasons when the major
      infecting strain of influenza in not one whose antigen is well covered by the vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Laboratory Confirmed Influenza Infections</measure>
    <time_frame>6 months</time_frame>
    <description>Four-fold increase in antibody titer 2 weeks post injection and end of study or positive laboratory test for influenza during study (polymerase chain reaction [PCR] or culture)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Adhering to Long-term Zanamivir Prophylaxis</measure>
    <time_frame>5 months</time_frame>
    <description>Number of subjects taking 80% or more doses per week of zanamivir (10 mg once daily), as influenza prophylaxis, for 13 weeks or longer (as measured by weekly diary and dose counts at study visits).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiviral prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zanamivir antiviral prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluviral</intervention_name>
    <description>One dose</description>
    <arm_group_label>Influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanamivir</intervention_name>
    <description>10 mg, OD, for duration of influenza season (10-23 weeks)</description>
    <arm_group_label>Antiviral prophylaxis</arm_group_label>
    <other_name>Relenza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-69 years old as of 01/Nov/2008

          -  have an understanding of the study, agree to its provisions, and give written informed
             consent prior to study entry

          -  available for follow-up during the study period

          -  if a women of child-bearing years, must meet criteria to prevent pregnancy

        Exclusion Criteria:

          -  allergy to any component of influenza vaccine or zanamivir

          -  previous serious adverse event associated with influenza vaccination

          -  receipt of influenza vaccine between 01/Mar/2008 and start of study

          -  previous adverse event associated with the use of antiviral medications

          -  expecting to be unable to take zanamivir for more than 72 hours during study period

          -  planning to spend more than 2 consecutive weeks outside Canada or more than 100 km
             from the study site during study period

          -  pregnant, or planning to become pregnant, during study period

          -  breastfeeding, or planning to breastfeed, a child under 12 months of age during study
             period

          -  receipt of immunoglobulin within six months of study entry

          -  immunocompromising condition or therapy that would be expected to reduce the efficacy
             of vaccination

          -  plans to receive cytotoxic or radiation therapy during study period

          -  history of cardiovascular or pulmonary disease that has required hospital admission
             within the past year

          -  history of asthma or other chronic respiratory disease

          -  participating in a trial that will result in the receipt of an investigational
             medication during the period that zanamivir may be taken (15/Nov/2008 to 30/Apr/2009)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allison McGeer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://microbiology.mtsinai.on.ca/research/HCW-Flu-Study/default.asp</url>
    <description>Mount Sinai Hospital</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <results_first_submitted>May 13, 2011</results_first_submitted>
  <results_first_submitted_qc>August 2, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2011</results_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <name_title>Dr. Allison McGeer/Director, Infection Control</name_title>
    <organization>Mount Sinai Hospital</organization>
  </responsible_party>
  <keyword>antiviral drugs</keyword>
  <keyword>influenza vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Zanamivir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 5th to November 19th, 2008 in Toronto, Ontario Canada. Most subjects were healthcare workers employed at a 470-bed acute care facility.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Influenza Vaccine</title>
          <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
        </group>
        <group group_id="P2">
          <title>Antiviral Prophylaxis</title>
          <description>Zanamivir, 10mg once daily during period of influenza activity, as prophylaxis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Influenza Vaccine</title>
          <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
        </group>
        <group group_id="B2">
          <title>Antiviral Prophylaxis</title>
          <description>Zanamivir, 10mg once daily during period of influenza activity, as prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="10"/>
                    <measurement group_id="B2" value="40" spread="10"/>
                    <measurement group_id="B3" value="40" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Adhering to Long-term Zanamivir Prophylaxis</title>
        <description>Number of subjects taking 80% or more doses per week of zanamivir (10 mg once daily), as influenza prophylaxis, for 13 weeks or longer (as measured by weekly diary and dose counts at study visits).</description>
        <time_frame>5 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine</title>
            <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>Antiviral Prophylaxis</title>
            <description>Zanamivir, 10mg once daily during period of influenza activity, as prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Adhering to Long-term Zanamivir Prophylaxis</title>
          <description>Number of subjects taking 80% or more doses per week of zanamivir (10 mg once daily), as influenza prophylaxis, for 13 weeks or longer (as measured by weekly diary and dose counts at study visits).</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="34" lower_limit="29" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Laboratory Confirmed Influenza Infections</title>
        <description>Four-fold increase in antibody titer 2 weeks post injection and end of study or positive laboratory test for influenza during study (polymerase chain reaction [PCR] or culture)</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Influenza Vaccine</title>
            <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
          </group>
          <group group_id="O2">
            <title>Antiviral Prophylaxis</title>
            <description>Zanamivir, 10mg once daily during period of influenza activity, as prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Laboratory Confirmed Influenza Infections</title>
          <description>Four-fold increase in antibody titer 2 weeks post injection and end of study or positive laboratory test for influenza during study (polymerase chain reaction [PCR] or culture)</description>
          <population>intention to treat</population>
          <units>infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>That in a year with mismatch between influenza vaccine antigen and infecting H3N2 strain, seasonal (10-13 weeks) antiviral prophylaxis in adults will provide better protection from symptomatic influenza infection than trivalent inactivated split virus influenza vaccine.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>4.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <desc>Solicited and unsolicited adverse event reporting</desc>
      <group_list>
        <group group_id="E1">
          <title>Influenza Vaccine</title>
          <description>Influenza vaccine, using Fluviral trivalent split virus vaccine</description>
        </group>
        <group group_id="E2">
          <title>Antiviral Prophylaxis</title>
          <description>Zanamivir, 10mg once daily during period of influenza activity, as prophylaxis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Broken bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="pneumonia">pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pilot study: Limited number of participants</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brenda Coleman</name_or_title>
      <organization>Mount Sinai Hospital</organization>
      <phone>416-586-4800 ext 4161</phone>
      <email>bcoleman@mtsinai.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

